Literature DB >> 2787847

In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.

J M Le Doussal1, M Martin, E Gautherot, M Delaage, J Barbet.   

Abstract

A method of pretargeted immunolocalization of a mouse cell subset, using dual specificity monoclonal antibody conjugates and labeled divalent haptens, is described. Conjugates were prepared by coupling F(ab')2 fragments of an antibody specific for the allelic mouse B cell antigen Lyb8.2, to Fab' fragments of an anti-2,4-dinitrophenyl antibody. Divalent and monovalent haptens were obtained by coupling dinitrophenyl to peptides or to diethylene-triamine-pentaacetic acid. In vitro, divalent haptens bind with higher affinity to mouse spleen lymphocyte-bound than to excess soluble conjugate (affinity enhancement). In vivo, localization of 125I- or 111In-labeled divalent haptens in mouse spleen is much higher than that of the monovalent analogs. Thus, using divalent haptens, a new kind of specificity to target cells was achieved, suggesting that affinity enhancement may improve target to background ratios in radioimmunoscintigraphy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787847

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  46 in total

1.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

2.  (99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.

Authors:  María Fernanda García; Xiuli Zhang; Manankumar Shah; Jessica Newton-Northup; Pablo Cabral; Hugo Cerecetto; Thomas Quinn
Journal:  Bioorg Med Chem       Date:  2016-01-29       Impact factor: 3.641

Review 3.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

Review 4.  Introduction to monoclonal antibodies.

Authors:  Jean-Pierre Mach
Journal:  Cancer Immun       Date:  2012-05-01

Review 5.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

Review 6.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

7.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

8.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 9.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

Review 10.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.